Jasper Therapeutics Refiles Phase 2b Protocol with $14.1M Cash, $1.2M Loss
Jasper Therapeutics refiled its Phase 2b CSU protocol with FDA and selected two dosing regimens after January data showing 67% complete response (n=6) and 75% response (n=36) in extension studies with a mean 31-point UAS7 reduction. Cash totaled $14.1 million at March 31 and net loss was $1.2 million ($0.04/share).
1. Clinical Progress
Jasper selected two active dosing regimens for its Phase 2b CSU study based on January data showing 67% complete response in BEACON (n=6) and 75% response in the open-label extension (n=36) with a mean 31-point UAS7 reduction, and refilled the updated protocol with the FDA.
2. Corporate Leadership
Jeet Mahal was appointed CEO to oversee the next clinical growth phase and lead efforts to secure additional funding for the Phase 2b study expected in the second half of the year.
3. Q1 Financial Results
As of March 31, cash and equivalents stood at $14.1 million, R&D expense was $5.8 million, G&A expense was $5.1 million, and net loss for the quarter was $1.2 million, or $0.04 per share.
4. Upcoming Catalysts
Jasper aims to commence its Phase 2b study in H2 after securing supplementary financing, with outcomes of the two dosing regimens poised to shape its clinical trajectory and funding requirements.